Clinical trials: IBS, Mixed Symptoms
IBS-C and IBS With Mixed Bowel Habits
Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS
Recent literature has demonstrated that the group of IBS sufferers who experience mixed bowel habits may be more similar to IBS-C patients than IBS-D patients.
- Trial name
- NCT00142987
- Testing
- Tegaserod
- Volunteers
- 664 people
- Sponsor
- Novartis
Irritable Bowel Syndrome
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts.
- Trial name
- BALANCE (NCT07519395)
- Testing
- Camlipixant
- Where
- 114 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
IBS, Diarrhea Predominant, IBS, Constipation Predominant
Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stress, and Bloating in IBS Diarrhea and Constipation Symptoms Using a Palm Pilot
Purpose: The associations between pain, stress, bloating, and their short interval temporal relationships to defecation in IBS D, C \& M are of great interest to the field of functional GI disorders, but have not been adequately…
- Conditions
- IBS, Diarrhea Predominant, IBS, Constipation Predominant, IBS, Mixed Symptoms
- Trial name
- NCT00619125
- Testing
- palm pilot recording responses to questionnaires
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Irritable Bowel Syndrome, Diarrhea
Fecal Microbiota Transplantation for IBS
The purpose of this study is to learn the efficacy and safety of fecal microbiota transplantation (FMT) using stool from a donor with low proteolytic activity and containing the bacteria Alistipes putredinis in patients with…
- Trial name
- NCT05776914
- Testing
- Donor Fecal Microbiota Transplantation, Autologous Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Madhusudan (Madhu) Grover, MBBS
Irritable Bowel Syndrome
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or…
- Trial name
- NCT03806127
- Testing
- Vibegron
- Where
- 41 sites in United States
- Volunteers
- 222 people
- Sponsor
- Urovant Sciences GmbH
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of…
- Conditions
- IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
- Trial name
- BoWell Sb252 (NCT07168434)
- Testing
- Saccharomyces Boulardii 250 MG
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 406 people
- Sponsor
- Biocodex
Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation
GOS to Reduce Symptom Severity in IBS
IBS is a highly prevalent bowel disorder, characterized by recurrent abdominal pain during bowel movements or a change in bowel habits.
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation, Irritable Bowel Syndrome - Diarrhoea, Irritable Bowel Syndrome - Mixed
- Trial name
- EGIS (NCT05157061)
- Testing
- Galacto-oligosaccharides (GOS), Maltodextrine
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 153 people
- Sponsor
- Clasado
Irritable Bowel Syndrome Mixed
The Effect of AI-based Microbiome Diet on IBS-M Symptoms
This study was designed as a pilot, open-labelled study. We enrolled consecutive IBS-M patients (n=25, 19 females, 46.06 ± 13.11 years) according to Rome IV criteria.
- Trial name
- NCT04768387
- Testing
- Personalized microbiome diet
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gazi University